This was not what I expected to read, and therefore much sadder to me. I had expected to see an article about the emotional strain of not knowing if you're in the control arm or the treatment arm for a late-stage trial. You know that you're in an experiment, and you might get a new drug -- or existing standard of care -- depending on a roll of the dice. This was very different. The author is describing a mad scramble…
None of this data will be published for a phase 1 study, but each participating doctor should have a copy of the investigators brochure, which contains all the preclinical data and clinical data up to this point. If you are taking a commercial medicine, the first place to check is the "prescribing information", which is publicly available and has all of the trial data, adverse events, efficacy, toxicology, interactio…
To a first approximation, about half of drug candidates fail in each phase of development (i.e. 50% drop off in every phase, from 1 to 3). Naïvely, then, about 80% of compounds tested in phase 1 will fail to become drugs.